Dr. John Cush RheumNow
3 years 2 months ago
Ultrasonography May Improve OA Pain Prediction
Dr. Bella Mehta reports on POS0107 from EULAR 2023 in Milan, Italy.
https://t.co/ZHBdWPWTys https://t.co/JLIScNVZGB
Dr. John Cush RheumNow
3 years 2 months ago
EULAR 2023 Lupus Highlights
https://t.co/CGybJRjDDK https://t.co/2kkB1hX2J5
Dr. John Cush RheumNow
3 years 2 months ago
Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?
The use of methotrextate with either bDMARDs, tsDMARDs or bsDMARDs was not shown to be cost effective, even though reduced disease activity and improved patient quality of life.
Read more--https://t.co/4nBp0ML8Kl https://t.co/5YXCotHlYK
Dr. John Cush RheumNow
3 years 2 months ago
Cancer Risk From RA, Not the Drugs
A large US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk.
https://t.co/6yrc0TsT53 https://t.co/WRQzeFoR1Z
Dr. John Cush RheumNow
3 years 2 months ago
An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately given METFORMIN or Placebo. Cumulative incidence of long COVID at day 300 was 6.3% w/ metformin vs 10.4% w/ placebo (HR 0.59; HR 037 if given w/in 3d) https://t.co/aCTX7xFewW https://t.co/xbBeED9K7U
Dr. John Cush RheumNow
3 years 2 months ago
Australian CRISTAL RCT 23 458 OA adults undergoing hip or knee replacements & given ASA 100 mg/d or SC enoxaparin 40 mg qd for 35 days (THR) or 14 days(TKR) for VTE prophylaxis = no difference betw groups: 90D mortality was 1.67% vs 1.53% https://t.co/wBLtlyCcsF https://t.co/WFkZ2KNHFF
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
About 60% of adults aged 18 and over reported taking at least one prescription medication in 2021, with 36% reporting taking three or more. Out-of-pocket costs on retail drugs rose 4.8% to $63 billion in 2021. High costs may limit individuals’ access to medications and lead to people not taking medication as prescribed; this may result in more serious illness and require additional treatment.
The FDA has approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.
Dr. John Cush RheumNow
3 years 2 months ago
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of RA receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
https://t.co/CVeAV0ZXA8 https://t.co/A8McLt0rSl
Dr. John Cush RheumNow
3 years 2 months ago
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
These included 5 overarching principles & 10 recos on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA.
https://t.co/OaRBNfhNCJ https://t.co/gF9QFDYTsu
Dr. John Cush RheumNow
3 years 2 months ago
Uncertainty can be worrisome. When uncertainty lies ahead, optimism and preparation are your best navigators. Im an optimist. https://t.co/JNzWJFMEfV https://t.co/ltIdy6hNqn
Dr. John Cush RheumNow
3 years 2 months ago
Medicare and Commercial claims analysis shows
1 #RA pts at risk for H Zoster
2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ
3 Higher total costsalso higher in month after HZ
https://t.co/gFlsLDIxVB https://t.co/733W3Kv3WC
